PF-06865571

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

HepatitisNon-Alcoholic Fatty Liver DiseaseNon-Alcoholic SteatohepatitisAlcoholic Fatty Liver Disease

237 competitors in Hepatitis

#DrugCompanyPhaseTrials

1

Cysteine Hydrochloride

Novartis

Phase 3

32

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

93

Crestor

AstraZeneca

Phase 3

14

PEG-Intron

Merck & Co.

Phase 3

—5

Aquasol E

NNational Eye Institute (NEI)

Phase 3

26

Amoxil

GGlobal Antibiotics Research and Development Partnership

Phase 3

17

Rimonabant

Sanofi

Phase 3

18

Cervarix

GSK

Phase 3

19

Prevnar

GSK

Phase 3

110

Hepatitis B Vaccine

Sanofi

Phase 3

1Show 22 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Adult Subject1 trial

Evaluation of Pharmacokinetic Drug Drug Interaction Between PF-05221304 And PF-06865571 In Healthy Adult Subjects

Completed·Pfizer·Phase 1·NCT03534648·16 enrolled

Adult1 trial

Relative Bioavailability Study of a Modified-Release Formulation of PF-06865571 in Healthy Adult Participants

Completed·Pfizer·Phase 1·NCT04044053·12 enrolled

Non-Alcoholic Fatty Liver Disease1 trial

A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.

Completed·Pfizer·Phase 2·NCT03776175·99 enrolled

Non-Alcoholic Steatohepatitis1 trial

Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)

Completed·Pfizer·Phase 2·NCT04321031·256 enrolled

Single Dose1 trial

Single Dose Study to Assess the Safety, Tolerability and Pharmacokinetics(PK) of PF-06865571

Completed·Pfizer·Phase 1·NCT03092232·17 enrolled

7 more indications

Alcoholic Fatty Liver Disease1 trial

2-Week Study In People With Nonalcoholic Fatty Liver Disease

Completed·Pfizer·Phase 1·NCT03513588·48 enrolled

Interaction1 trial

Drug-Drug Interaction Study to Evaluate the Effect of PF-06865571 on Metformin Pharmacokinetics

Completed·Pfizer·Phase 1·NCT03593707·18 enrolled

Hepatitis1 trial

Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis

Completed·Pfizer·Phase 2·NCT04399538·75 enrolled

Overweight1 trial

A Study To Assess The Safety, Tolerability, And Pharmacokinetics (PK) Of Multiple Doses Of PF-06865571 In Healthy, Including Overweight And Obese, Adult Subjects

Completed·Pfizer·Phase 1·NCT03230383·60 enrolled

Absorption1 trial

A Study in Healthy Adult Male Participants to Assess Absorption, Distribution, Metabolism and Excretion (ADME) of Radiolabeled PF-06865571.

Completed·Pfizer·Phase 1·NCT04866225·6 enrolled

Hepatic Impairment1 trial

Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects

Completed·Pfizer·Phase 1·NCT04091061·24 enrolled

Unspecified1 trial

A Study To Evaluate Different Formulations Of PF-06865571 In Healthy Subjects

Completed·Pfizer·Phase 1·NCT03372044·12 enrolled

Details

Drug Info

Related News